486 related articles for article (PubMed ID: 31926287)
21. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
[TBL] [Abstract][Full Text] [Related]
23. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
[TBL] [Abstract][Full Text] [Related]
26. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
[TBL] [Abstract][Full Text] [Related]
28. D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.
Turkova A; Chan MK; Kityo C; Kekitiinwa AR; Musoke P; Violari A; Variava E; Archary M; Cressey TR; Chalermpantmetagul S; Sawasdichai K; Ounchanum P; Kanjanavanit S; Srirojana S; Srirompotong U; Welch S; Bamford A; Epalza C; Fortuny C; Colbers A; Nastouli E; Walker S; Carr D; Conway M; Spyer MJ; Parkar N; White I; Nardone A; Thomason MJ; Ferrand RA; Giaquinto C; Ford D;
Contemp Clin Trials; 2024 Jul; 142():107540. PubMed ID: 38636725
[TBL] [Abstract][Full Text] [Related]
29. Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
Acosta RK; D'Antoni ML; Mulato A; Yant SR; Cihlar T; White KL
Antimicrob Agents Chemother; 2022 May; 66(5):e0203821. PubMed ID: 35389236
[TBL] [Abstract][Full Text] [Related]
30. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Rutherford GW; Horvath H
PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
[TBL] [Abstract][Full Text] [Related]
32. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
[TBL] [Abstract][Full Text] [Related]
33. New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.
Ribera E
AIDS Rev; 2018; 20(4):179-186. PubMed ID: 30548024
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
[TBL] [Abstract][Full Text] [Related]
35. Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.
Hester EK; Astle K
Ann Pharmacother; 2019 Aug; 53(8):860-866. PubMed ID: 30758229
[No Abstract] [Full Text] [Related]
36. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
37. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
[TBL] [Abstract][Full Text] [Related]
39. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
[TBL] [Abstract][Full Text] [Related]
40. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
